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Abstract
Background: In the search for generic expression strategies for mammalian protein families
several bacterial expression vectors were examined for their ability to promote high yields of
soluble protein. Proteins studied included cell surface receptors (Ephrins and Eph receptors,
CD44), kinases (EGFR-cytoplasmic domain, CDK2 and 4), proteases (MMP1, CASP2), signal
transduction proteins (GRB2, RAF1, HRAS) and transcription factors (GATA2, Fli1, Trp53, Mdm2,
JUN, FOS, MAD, MAX). Over 400 experiments were performed where expression of 30 full-length
proteins and protein domains were evaluated with 6 different N-terminal and 8 C-terminal fusion
partners. Expression of an additional set of 95 mammalian proteins was also performed to test the
conclusions of this study.
Results:  Several protein features correlated with soluble protein expression yield including
molecular weight and the number of contiguous hydrophobic residues and low complexity regions.
There was no relationship between successful expression and protein pI, grand average of
hydropathicity (GRAVY), or sub-cellular location. Only small globular cytoplasmic proteins with an
average molecular weight of 23 kDa did not require a solubility enhancing tag for high level soluble
expression. Thioredoxin (Trx) and maltose binding protein (MBP) were the best N-terminal
protein fusions to promote soluble expression, but MBP was most effective as a C-terminal fusion.
63 of 95 mammalian proteins expressed at soluble levels of greater than 1 mg/l as N-terminal H10-
MBP fusions and those that failed possessed, on average, a higher molecular weight and greater
number of contiguous hydrophobic amino acids and low complexity regions.
Conclusions: By analysis of the protein features identified here, this study will help predict which
mammalian proteins and domains can be successfully expressed in E. coli as soluble product and also
which are best targeted for a eukaryotic expression system. In some cases proteins may be
truncated to minimise molecular weight and the numbers of contiguous hydrophobic amino acids
and low complexity regions to aid soluble expression in E. coli.
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Background
The production of purified proteins is important for sev-
eral experimental approaches aimed to assign gene func-
tion including antibody generation for
immunocytochemistry and immunoprecipitation studies
[1-3], in vitro mapping of protein – protein, protein –
DNA or protein – RNA interactions [4,5] and structure
determination [6]. The availability of proteins is also
important for biomedical applications such as small mol-
ecule drug discovery and the production of therapeutic
proteins and vaccines. In these situations it is essential to
be able to reliably express the proteins in a heterologous
system and purify them so that they possess the same
folds and structure as they would in a natural in vivo state.
To achieve this on a whole proteome scale a generic
approach must be taken to the expression of protein fam-
ilies, unlike the traditional approach of protein chemistry
in optimising the isolation of individual proteins on a
case by case basis. E. coli has been the expression system
of choice for the majority of laboratories engaged in high-
throughput, multi-plexed cloning, expression and purifi-
cation of proteins for structural genomics [7]. The advan-
tages of E. coli as an expression host include well studied
physiology, genetics and availability of advanced genetic
tools [8-10], rapid growth, high-level protein production
rates achieving up to 10–30% of total cellular protein,
ease of handling in a standard molecular biology labora-
tory, low cost and the ability to multiplex both expression
screening [11] and protein production [12]. There are
however several disadvantages, particularly for eukaryotic
proteins, of expression in a prokaryotic system. The lack of
eukaryotic chaperones, specialised post-translational
modifications, ability to be targeted to sub-cellular loca-
tions or to form complexes with stabilising binding part-
ners can result in protein mis-folding and aggregation. For
example, when 2078 randomly selected C. elegans full-
length genes were cloned and expressed in E. coli only 11
% yielded soluble protein [13]. Similarly for 44 cloned
human proteins, 12 were expressed solubly and 4 purified
to homogeneity [14]. With the exception of full-length
membrane proteins, the property of protein solubility has
been shown to be a good indicator of correct folding as
determined by functional binding [15,16] or enzymatic
[17] assays. Purification of inclusion bodies and in vitro
refolding has been used in a number of cases, but refold-
ing conditions are highly protein specific and so unlikely
to be useful for high-throughput protein expression.
There are several fall-back strategies for expression of cor-
rectly folded eukaryotic proteins in E. coli one of which is
to truncate long multi-domain proteins into separate
domains, as has been performed for the Ephb2 receptor
[15,18,19]. Reducing translation rates so that proteins
have an increased chance of folding into a native state
prior to aggregating with folding intermediates, can be
successful by lowering the temperature after induction
[20] or inducing with lower concentrations of IPTG [21].
Alternate approaches include: co-expressing stabilising
binding partners (see review [7]) or chaperones [22]; the
induction of chaperones by heat shock [23] or chemical
treatment [24]; or the use of genetically modified host-
strains that can conduct oxidative protein folding in the
cytoplasm [25,26], over-express rare tRNAs [27] or lipid
rafts [28]. Perhaps one of the most successful generic strat-
egies to enhance the expression of soluble proteins is the
fusion with solubility enhancing tags, such as maltose
binding protein (MBP), thioredoxin (Trx) and glutath-
ione-S-transferase (GST) [29-31].
The aim of this work was to ask if it is possible to derive
some general conclusions regarding which expression
strategy would most likely result in the expression of sol-
uble, functionally active mammalian protein on a family-
by-family or domain-by-domain basis. A deep-mining
approach was taken to maximise the chances of successful
expression by examining the soluble expression of 30 dif-
ferent proteins using 14 different expression vectors. This
study allowed us to make several conclusions regarding
the best strategies to adopt for the soluble expression of
different mammalian proteins in bacteria. The conclu-
sions were tested by the expression of an additional 95
mammalian proteins.
Results
Expression clone construction
The 30 proteins chosen for this expression study are listed
in Table 1. With the exception of GFP, they are all human
or mouse proteins, and represent several diverse protein
families with extra-cellular, cytoplasmic and nuclear cell
locations. The list includes a mixture of full-length and
truncated proteins expected to be easy or more challeng-
ing to express in a bacterial system. Protein truncations
were designed to express individual domains annotated
from the SwissProt [32] or Pfam [33] databases or follow-
ing previous examples of successful expression [15]. The
genes were isolated from cDNA using a nested PCR strat-
egy [34] or provided by the FlexGene Consortium http://
www.hip.harvard.edu/flex_gene/index.htm and sequence
confirmed. A recombinational cloning strategy was
employed termed "GATEWAY" cloning [35,36] based on
a modification of the phage lambda site-specific recombi-
nation system [37]. Primers were designed using the near-
est neighbour algorithm [38] and open reading frames
(ORFs) were PCR amplified from first strand cDNA with
5' attB1 and 3' attB2 linkers and then recombined with
pDONR221 (Invitrogen) to give a set of entry clones
which were sequence confirmed and then recombined
with various destination vectors to give the expression
constructs. Two sets of clones for each ORF were generated
with and without stop codons for expression with N or C-BMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
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terminal tags respectively. Recombinational cloning was
useful in this study where the same set of ORFs could be
cloned into a large set of different expression vectors with-
out the requirement to check for compatible restriction
sites in each vector or their absence within the ORFs.
For this study a set of destination vectors were constructed
by modifying pET-DEST42 (see Materials and Methods).
The T7 promoter was chosen over other promoters com-
monly used for bacterial expression because of the high
specificity and processivity of T7 RNA polymerase and the
wide choice of expression strains currently available.
Briefly, multicloning sites were created either 5' of the
attR1 or 3' of the attR2 recombination sites for insertion
of DNA inserts encoding N or C-terminal tags respectively.
The expression vectors contained a T7lac promoter [39]
for improved control of basal expression. The N-terminal
tag expression vectors contained a sequence at the transla-
tional start site to provide a partial match with the down-
stream box (ATG AAT CAC CAT), shown to provide
enhancement of translation [40] and a decahistidine
(H10) tag for enhanced affinity for Nickel resins com-
Table 1: Proteins for expression study with selected features
No Proteina Domain
b
Constructc Organis
md
Protein Familye MW 
(Kda)
pI Cys 
%
GRAVY
f
hp_aag Sub-cellular 
Location
LCh CCi
26 CASP2 FL 1–435/435 Hs CARD, 
Peptidase_C14
48.9 6.3 4.1 -0.30 5 Cytoplasm 1 0
24 CCND2 FL 1–289/289 Hs cyclin, cyclin_C 33.1 4.9 4.1 -0.21 4 Cytoplasm 2 0
29 CD44 FL 1–742/742 Hs Xlink, Pfam-B × 9 81.6 5.0 1.2 -0.77 10 Extra-cellular 9 0
22 CDK2 FL 1–298/298 Hs pkinase 33.9 8.9 1 -0.08 4 Cytoplasm 0 0
23 CDK4 FL 1–303/303 Hs pkinase 33.7 6.6 1.3 -0.17 4 Cytoplasm 0 0
25 CDKN1B FL 1–198/198 Hs CDI, Pfam-B × 2 22.1 6.6 2 -1.26 2 Cytoplasm 0 1
28 CDKN2A FL 1–156/156 Hs ank 16.5 5.4 0.6 -0.23 4 Cytoplasm 0 0
6 Efna1 FL 18–205/205 Mm Ephrin 21.9 6.4 2.1 -0.59 8 Extra-cellular 1 0
7 Efna1 EC 18–154/205 Mm Ephrin 16.2 6.5 2.9 -0.86 2 Extra-cellular 0 0
5 Efnb2 EC1 29–176/336 Mm Ephrin 16.6 5.3 2.7 -0.47 3 Extra-cellular 0 0
4 Efnb2 EC2 29–210/336 Mm Ephrin 20.1 8.6 2.2 -0.64 3 Extra-cellular 0 0
15 EGFR TK 694–1022/
1210
Hs Pkinase, Pfam-B 37.3 5.5 1.8 -0.22 3 Cytoplasm 1 0
8 Epha2 LB 24–206/977 Mm EPH_lbd 21.1 4.7 2.7 -0.30 4 Extra-cellular 0 0
1 Ephb2 LB 28–210/994 Mm EPH_lbd 22.5 5.8 2.2 -0.14 4 Extra-cellular 0 0
3 Ephb2 SAM 922–994/994 Mm SAM_1 8.3 4.9 0 -0.03 2 Cytoplasm 0 0
2 Ephb2 TK 595–906/994 Mm Pkinase 35.3 5.6 1.6 -0.27 5 Cytoplasm 0 0
10 Fli1 FL 1–452/452 Mm Ets, SAM_PNT, 
Pfam-B × 5
51.0 6.6 0.9 -0.79 3 Nuclear 1 0
19 FOS FL 1–380/380 Hs bZIP, Pfam-B × 4 40.7 4.6 2.1 -0.37 5 Nuclear 5 1
9 GATA2 FL 1–480/480 Hs GATA 50.3 9.7 2.7 -0.51 13 Nuclear 7 0
30 GFP FL 1–238/238 Av GFP 26.9 5.6 0.8 -0.52 3 Cytoplasm 0 0
14 GRB2 FL 1–217/217 Hs SH2, SH3 25.2 5.9 0.9 -0.67 5 Cytoplasm 0 0
17 HRAS FL 1–189/189 Hs ras 21.3 5.0 3.2 -0.42 4 Cytoplasm 1 0
18 JUN FL 1–331/331 Hs bZIP, Jun 35.7 9.0 0.9 -0.47 3 Nuclear 3 1
20 MAD FL 1–221/221 Hs HLH, Pfam-B × 2 25.3 8.9 1.4 -0.97 2 Nuclear 3 1
21 MAX FL 1–160/160 Hs HLH, Pfam-B × 2 18.3 5.9 0 -1.32 2 Nuclear 1 1
12 Mdm2 FL 1–489/489 Mm SWIB, zf-RanBP, 
Pfam-B × 8
54.5 4.5 3.5 -0.83 4 Nuclear / 
Cytoplasm
50
13 Mdm2 p53-bd 19–230/489 Mm SWIB, Pfam-B × 2 11.7 8.8 0.5 -0.25 4 Nuclear / 
Cytoplasm
30
27 MMP1 FL 1–469/469 Hs Peptidase_M10_N, 
Peptidase_M10, 
Hemopexin
54.0 6.5 0.6 -0.57 7 Extra-cellular 0 0
16 RAF1 Ras-bd 51–131/648 Hs RBD 9.2 9.9 3.8 -0.30 3 Cytoplasm 0 0
11 Trp53 FL 1–390/390 Mm P53 43.5 7.0 3.1 -0.59 3 Nuclear / 
Cytoplasm
10
aLocusLink symbol. bDomain: LB, ligand binding; TK, tyrosine kinase; SAM, sterile alpha motif; EC, extra-cellular; FL, full-length; bd, binding domain. 
cConstruct expressed numbered by amino acid position (start – finish / total). dOrganism: Mm, Mus musculus; Hs, Homo sapiens; Av, Aequoria 
Victoria. eProtein family nomenclature according to the Pfam database http://www.sanger.ac.uk/Software/Pfam/. fGRAVY, grand average of 
hydropathicity index. gHighest number of contiguous hydrophobic amino acids (A, V, I, L, W or F). hLC and iCC, number of low complexity and 
coiled coil regions according to Pfam database.BMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
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Expression vector constructs after recombination between the destination and entry plasmids Figure 1
Expression vector constructs after recombination between the destination and entry plasmids. (A) Schematic 
representation where shaded and clear boxes indicate translated and untranslated regions respectively. T7 = T7 RNA 
polymerase promoter, lacO = lac operator, SD = shine dalgarno, H6 or H10 = hexahistidine or decahistidine, attB1 or attB2 = 
attB recombination sites, ORF = open reading frame, stop = stop codon, fusion = protein fusion (MBP, GFP, GST, Trx, DHFR 
or Dhfr), V5 = V5 epitope. (B) and (C) DNA sequences of pDEST-N112 and pDESTC102 respectively from T7 RNA polymer-
ase promoter to stop codon.
T7 SD H6 attB1 ORF stop attB2 pDEST17
pDEST-N110 T7 lacO SD H10 attB1 ORF stop attB2
pET-DEST42 H6 attB2 ORF stop V5 T7 lacO attB1 SD
pDEST-C101 H10 attB2 ORF stop T7 lacO attB1 SD
pDEST-N112 T7 lacO SD H10 attB1 ORF stop attB2 fusion
DraIII BfrBI
pDEST-C102 T7 lacO attB1 SD attB2 ORF H10 stop fusion
DraIII BfrBI
A
    T7 promoter              lac operator                                                             RBS 
     |                         |                                                                       |
     |        10           20  |        30            40           50           60            70       |   80      
   ATT AAT ACG ACT CAC TAT AGG GGA ATT GTG AGC GGA TAA CAA TTC CCC TCT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA GAT 
      NdeI                                                KpnI    DraIII      BfrB1   attB1 recombination site       
       |                                                   |       |           |       | 
       |90           100          110          120         | 130   |      140  |       150           160           
   ATA CAT ATG AAT CAC CAT CAC CAT CAC CAT CAC CAT CAC CAT GGT ACC CAC GAA GTG ATG CAT ACA AGT TTG TAC AAA AAA GCA 
            M   N   H   H   H   H   H   H   H   H   H   H   G   T   H   E   V   M   H   T   S   L   Y   K   K   A 
                          attB2 recombination site 
                           |
                      Stop | 
                       |   |
  170          180     |   | 190          200          210    
   GGC TCT NNN NNN NNN TAG AAC CCA GCT TTC TTG TAC AAA GTG GT
    G   S       ORF     * 
  T7 promoter             lac operator 
   |                        |
   |          10           20           30            40           50           60            70           80      
   TAA TAC GAC TCA CTA TAG GGG AAT TGT GAG CGG ATA ACA ATT CCC CTC TAG AAA TAA TTT TGT TTA ACT TTA AGA AGG AAT ATC 
 >attB1                               RBS            initiation codon     attB2 recombination site           DraIII 
   |                                   |                   |               |                                   | 
   |    90           100          110  |       120         | 130          140          150           160       |   
   ACA AGT TTG TAC AAA AAA GCA GGC TTC GAA GGA GAT AGA ACC ATG NNN NNN NNN AAC CCA GCT TTC TTG TAC AAA GTG GTG CAC 
                                                            M       ORF     N   P   A   F   L   Y   K   V   V   H 
                  BfrB1                                       Stop 
                   |                                           | 
  170          180 |         190          200          210     |   
   GAA GTG AGT GGT ATG CAT CAC CAT CAC CAT CAT CAC CAT CAC CAT TGA
    E   V   S   G   M   H   H   H   H   H   H   H   H   H   H   *
B
CBMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
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pared with hexahistidine (H6) tags (data not shown). A
fusion partner was inserted between the H10 tag and
recombination sites to examine the effect on soluble pro-
tein expression. Unlike previous tag comparisons [29-31]
here the same promoter and 5'-UTR sequence was
employed so that any expression differences observed
would be purely due to the presence the fusion partner. A
vector was also included in this study (pDEST17) with a
T7 promoter and no downstream lac operator, which
would add a H6 tag at the N-terminus (Figure 1).
Effect of different N-terminal fusions on expression
Expression plasmids generated by recombination reac-
tions were used to transform E. coli BL21(DE3), an expres-
sion strain containing chromosomally integrated T7 RNA
polymerase gene (λDE3 lysogen) under the control of the
lacUV5 promoter. To handle a large number of expression
experiments (420 total) and associated manipulations to
screen for total and soluble expression in E. coli, the
recombinational cloning, transformation, growth of
expression cultures and cell lysis and filtration separation
of insoluble protein were performed in 96-well plate for-
mat. Figure 2 shows Western blots for total and soluble
protein expression 2 hours after induction with 1 mM
IPTG as described in Materials and Methods. The method
for separating total from soluble proteins was based on
that of Knaust and Nordlund [11] and consisted of deter-
gent lysis of harvested cells followed by filtration through
a 0.65 µm 96-well filter plate, which separates larger
inclusion bodies from the soluble fraction. The filtration
method agrees well with traditional centrifugation meth-
ods to separate soluble from insoluble protein [11,41]
and has the advantage that multiple samples can be proc-
essed in parallel. Quantitation was achieved by separating
the proteins by SDS-PAGE, electro-blotting onto PVDF
membranes and detecting His tagged proteins with an
anti-His5 monoclonal antibody followed by probing with
an anti-mouse Cy-5 labelled antibody. The advantage of
expression analysis by Western blot, compared to dot-
blots, is that this allows one to quantitate the expression
levels of full-length constructs and eliminate the contribu-
tion from cleaved protein tag. It was found that Western
blots based on fluorescence detection [42] gave a greater
dynamic range of detection compared with detection
based on enzymatic amplification such as horse radish
peroxidase (data not shown). A His-tagged protein molec-
ular weight ladder was used for normalisation to elimi-
nate any blot to blot variation. Table 2 shows the results
of this analysis, quantitating expression yields in terms of
mg expressed protein per litre of induction media for total
and soluble expression. Expression yields greater than 2
mg/l are highlighted in bold.
Looking first at the results for total (soluble and insolu-
ble) expression, no clear patterns emerge for the various
expression vectors used. With the exception of CASP2,
Effect of N-terminal fusion on protein expression Figure 2
Effect of N-terminal fusion on protein expression Total (A) and soluble (B) expression for protein 1 – 30 (Table 1) with 
various N-terminal fusion partners analysed by SDS-PAGE fluorescence western blots as described in Materials and Methods. 
Expression plasmids employed were (a) pDEST17, (b) pDEST-N110 or pDEST-N112 with either (c) MBP, (d) GFP, (e) GST or 
(f) Trx inserted between the DraIII and BfrBI sites as shown in Figure 1.
A – Total Expression B – Soluble Expression
d
e
f
m1 9 21 0 31 141 251 361 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 72 51 82 61 92 72 02 82 12 92 2   5   2 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16
m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16
a
b
c
m1 9 21 0 31 141 2 5 1 361 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 2 1 0 31 141 2  51 361 4  71 581 6m1 72 51 82 61 92 72 02 82 12 92 2  5  2 33 02 4
m1 9 21 0 31 141 2 51 3 61 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
d
e
f
m1 9 21 0 31 141 251 361 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 72 51 82 61 92 72 02 82 12 92 2   5   2 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16
m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16
d
e
f
d
e
f
m1 9 21 0 31 141 251 361 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 72 51 82 61 92 72 02 82 12 92 2   5   2 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16
m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16
m1 9 21 0 31 141 251 361 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 141 251 361 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 141 251 361 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 72 51 82 61 92 72 02 82 12 92 2   5   2 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16 m1 72 51 82 61 92 72 02 82 12 92 2   5   2 33 02 4 m1 9 21 0 31 141 251 361 471 5 81 6m1 72 51 82 61 92 72 02 82 12 92 2   5   2 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16
m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 141 251 361 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16
a
b
c
m1 9 21 0 31 141 2 5 1 361 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 2 1 0 31 141 2  51 361 4  71 581 6m1 72 51 82 61 92 72 02 82 12 92 2  5  2 33 02 4
m1 9 21 0 31 141 2 51 3 61 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
a
b
c
a
b
c
m1 9 21 0 31 141 2 5 1 361 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 2 1 0 31 141 2  51 361 4  71 581 6m1 72 51 82 61 92 72 02 82 12 92 2  5  2 33 02 4
m1 9 21 0 31 141 2 51 3 61 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 21 0 31 141 2 5 1 361 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 141 2 5 1 361 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 141 2 5 1 361 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 2 1 0 31 141 2  51 361 4  71 581 6m1 72 51 82 61 92 72 02 82 12 92 2  5  2 33 02 4 m1 9 2 1 0 31 141 2  51 361 4  71 581 6m1 72 51 82 61 92 72 02 82 12 92 2  5  2 33 02 4 m1 9 2 1 0 31 141 2  51 361 4  71 581 6m1 72 51 82 61 92 72 02 82 12 92 2  5  2 33 02 4
m1 9 21 0 31 141 2 51 3 61 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 141 2 51 3 61 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 141 2 51 3 61 471 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
15
30
50
75
100
15
30
50
75
100
15
30
50
75
100
15
30
50
75
100
15
30
50
75
100
15
30
50
75
100
15
30
50
75
100
15
30
50
75
100
15
30
50
75
100
15
30
50
75
100
15
30
50
75
100
kDa
kDa
kDa
kDa
kDa
kDa
m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 2 1 0 3 1 1 41 2  5 1 3 61 4  71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
a
b
c
m1 9 21 0 31 141 25 1 361 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m 1 9 2 10 3 11 4 12 5 13 6 14 7    15 8 16 m 17 25 18 26 19 27 20 28 21 29 22 5 23 30 24
d
e
f
m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 2 1 0 3 1 1 41 2  5 1 3 61 4  71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
a
b
c
m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 21 0 31 1 41 2 5 1 3 61 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m1 9 2 1 0 3 1 1 41 2  5 1 3 61 4  71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 2 1 0 3 1 1 41 2  5 1 3 61 4  71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4 m1 9 2 1 0 3 1 1 41 2  5 1 3 61 4  71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
a
b
c
a
b
c
m1 9 21 0 31 141 25 1 361 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m 1 9 2 10 3 11 4 12 5 13 6 14 7    15 8 16 m 17 25 18 26 19 27 20 28 21 29 22 5 23 30 24
d
e
f
m1 9 21 0 31 141 25 1 361 4 71 581 6 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m 1 9 2 10 3 11 4 12 5 13 6 14 7 15 8 16 m1 72 51 82 61 92 72 02 82 12 92 252 33 02 4
m 1 9 2 10 3 11 4 12 5 13 6 14 7    15 8 16 m 17 25 18 26 19 27 20 28 21 29 22 5 23 30 24
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CDKN2A, Trp53, EGFR(TK), FOS and CD44 most pro-
teins expressed well across all expression vectors. Interest-
ing differences are apparent however when one looks at
the production of soluble protein. Using decahistidine
green fluorescent protein (H10-GFP) or decahistidine glu-
tathione-S-transferase (H10-GST) as fusion partners at the
N-terminus gave poor yields of soluble intact product.
This may not be because they were poor at promoting sol-
uble expression but because they were prone to proteoly-
sis during cell lysis reducing the yield of full-length
soluble protein. A set of proteins (GFP, RAF1(Ras-bd),
HRAS, mdm2(p53-bd), Ephb2(TK) and CCND2) gave
high soluble expression levels in the baseline N-terminal
decahistidine vector, which was not improved when
expressed as decahistidine thioredoxin (H10-Trx) or deca-
histidine maltose binding protein (H10-MBP) fusions.
The molecular weight of these proteins ranged from 9 – 35
Kda and averaged 22.8 Kda. These proteins are all
expressed in the cytoplasm, have an average of 1 low-com-
plexity region, 3.8 contiguous hydrophobic amino acids
(hp_aa), pI of 6.6, grand average of hydropathicity index
(termed GRAVY[43] where increased positive number
indicates increased hydrophobicity) of -0.32, 2.6%
cysteine residues and no coiled-coil structures. A second
grouping of proteins was observed where soluble
expression was improved when expressed as H10-Trx or
H10-MBP fusions compared with the H10 tag alone. This
grouping included GRB2, Efnb2(EC1 or 2), MAD, MAX,
Efna1 (FL and EC). The molecular weight of these proteins
ranged from 16 – 25 Kda and averaged 20.5 Kda. These
proteins were a mixture of those expressed in the cyto-
plasm, nucleus and extra-cellular, have an average of 0.71
Table 2: N-Terminal fusion expression comparison
N-TERMINAL FUSION
Protein (domain) H6 H10 H10-GFP H10-GST H10-Trx H10-MBP
TSTSTSTSTSTS
CASP2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.20 2.50 2.11
CCND2 21.85 0.00 12.36 5.81 6.14 0.02 1.20 0.00 12.50 4.35 8.12 3.06
CD44 0.00 0.00 0.00 0.00 0.00 0.00 nc nc 0.00 0.00 0.00 0.00
CDK2 14.81 1.84 1.03 0.07 nc nc 4.88 2.17 2.00 1.54 25.00 25.00
CDK4 8.78 0.71 1.47 1.37 nc nc 1.32 0.00 nc nc 2.79 0.00
CDKN1B 7.44 0.17 0.85 0.31 1.63 0.57 12.00 4.30 4.00 1.69 8.00 5.19
CDKN2A 0.00 0.00 0.00 0.00 0.00 0.00 0.40 0.32 nc nc 3.65 0.00
Efna1 0.00 0.03 1.50 1.33 7.47 0.22 2.29 0.06 nc nc 5.73 3.02
Efna1 (EC) 24.74 0.05 5.00 4.81 50.00 1.71 28.00 0.07 60.00 4.10 11.93 4.93
Efnb2 (EC1) 3.58 0.00 11.53 1.18 10.38 0.86 6.43 1.30 44.70 6.82 22.67 20.00
Efnb2 (EC2) 2.07 0.04 3.00 2.79 50.00 6.50 55.00 0.00 nc nc 17.00 16.00
EGFR (TK) 0.00 0.00 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Epha2 (LB) nc nc nc nc 50.00 0.43 2.83 0.05 4.92 1.99 14.57 3.78
Ephb2 (LB) 40.00 0.00 0.66 0.08 4.93 0.14 10.00 0.03 29.39 2.53 20.00 2.11
Ephb2 (SAM) 0.00 0.00 nc nc 50.00 5.63 35.00 11.47 10.06 1.34 0.00 0.00
Ephb2 (TK) 0.00 0.00 65.84 15.00 20.00 0.35 15.00 0.14 50.00 14.23 20.00 4.15
Fli1 3.82 0.05 0.89 0.08 2.00 0.00 1.50 0.00 12.00 5.14 58.00 6.50
FOS 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.49 0.08 0.27 0.00
GATA2 0.33 0.00 0.19 0.07 2.50 0.04 0.00 0.00 5.00 3.47 0.00 0.00
GFP 60.00 60.00 25.00 25.00 25.00 1.33 22.08 20.00 25.00 25.00 10.00 9.83
GRB2 1.75 0.04 6.00 3.88 25.00 12.82 2.77 0.84 13.00 11.96 18.00 16.00
HRAS 30.10 0.34 6.40 5.59 6.16 0.17 7.37 0.54 26.96 25.00 8.40 7.69
JUN 40.00 0.00 5.84 1.09 2.08 0.00 1.50 0.00 5.70 0.41 30.00 0.22
MAD 32.77 0.15 3.50 1.78 20.66 0.37 15.04 0.13 9.21 4.74 4.00 4.10
MAX nc nc 9.43 1.09 4.44 1.18 0.00 0.03 2.05 2.01 3.00 2.71
Mdm2 0.00 0.00 1.20 0.91 0.00 0.00 0.00 0.00 10.00 5.57 3.60 2.65
Mdm2 (p53-bd) 1.62 0.36 4.75 4.70 20.84 3.20 20.00 0.22 9.54 4.72 12.00 12.00
MMP1 2.56 0.00 0.36 0.10 11.44 0.00 39.63 0.04 0.32 0.32 30.00 0.48
RAF1 (Ras-bd) 15.48 15.00 20.00 20.00 26.92 0.00 20.00 19.82 25.00 25.00 40.00 25.00
Trp53 0.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
AVERAGE 11.36 0.81 7.28 3.27 10.53 1.01 9.02 1.37 15.90 6.02 14.87 5.81
Numbers correspond to total (T) or soluble (S) expression yield (mg/l). Yields greater than 2 mg/l are in bold, nc-not cloned.BMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
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low-complexity regions, 3.6 contiguous hydrophobic
amino acids (hp_aa), pI of 6.8, GRAVY score of -0.79 and
1.7% cysteines. A third set of proteins resulted in almost
undetectable soluble expression with a H10 tag but good
expression with H10-Trx or H10-MBP fusions. These
included CDK2, FLI1, CDKN-1B, mdm2, GATA2,
Ephb2(LB) and CASP2 with molecular weights ranging
from 22.5 – 54.5 Kda, with an average molecular weight
of 40.4 Kda. These proteins were also a mixture cytoplas-
mic, nuclear and extra-cellular proteins, have an average
of 2 low-complexity regions, 5 contiguous hydrophobic
amino acids (hp_aa), pI of 6.9, GRAVY score of -0.55 and
2.3% cysteines. Finally a set of proteins was grouped
(MMP1, FOS, EGFR(TK), Trp53, CD44) where very low (<
1 mg/l) soluble full-length expression was observed, even
when expressed as MBP or Trx fusions. Here the molecular
weight ranged from 40.7 – 81.6 Kda and averaged 51.4
kDa. These proteins were a mixture of those expressed in
the cytoplasm, nucleus and extra-cellular, have an average
of 3 low-complexity regions, 5.6 contiguous hydrophobic
amino acids (hp_aa), pI of 5.7, GRAVY score of -0.50 and
1.8% cysteine content.
Comparing the 20 mammalian proteins where there are
examples in all 6 expression vectors the average yields of
soluble protein for the H10, H10-GFP, H10-GST, H10-Trx
and H10-MBP tags are 3.3, 1.0, 1.4, 6.0 and 5.8 mg per
litre of culture. This ranks the ability of the tag fusions to
produce full-length soluble protein as H10-Trx ~ H10-
MBP > H10 > H10-GST > H10-GFP. The pDEST17 vector
(which encodes a H6 tag) was dramatically poorer at
expressing soluble protein compared with the vector
pN110 (which encodes a H10 tag), with average soluble
expression yields of 0.8 and 3.3 mg per litre of culture
respectively. Both vectors contain T7 RNA polymerase
promoters, but pN110 also contains a lac operator (lacO)
downstream of the promoter and the gene encoding the
lac repressor (lacI) for tighter control of gene expression.
This may result in a faster rate of transcript synthesis, after
induction with IPTG, and hence translation rates (due to
an increased concentration of mRNA) for pDEST17
compared with pN110. If translation rate exceeds the rate
of protein folding, then increased production of insoluble
protein would occur.
Effect of different C-terminal fusions on expression
A similar study was performed where the 30 ORFs were
cloned into 8 different C-terminal tag expression vectors
shown in Figure 1. C-terminal fusions studied here
included V5-H6 or H10 or protein fusions MBP, GST, Trx,
murine or human dihydrofolate reductase (Dhfr or DHFR
respectively), all with H10 at the C-terminus. The expres-
Effect of C-terminal fusion on protein expression Figure 3
Effect of C-terminal fusion on protein expression Total (T) and soluble (S) expression for protein 1 – 30 (Table 1) with 
different C-terminal fusion partners analysed by SDS-PAGE fluorescence western blots as Figure 2. Expression plasmids 
employed were (g) pET-DEST42, (h) pDEST-C101 or pDEST-C102 with either (i) MBP, (j) GST, (k) GFP (l) Trx (m) Dhfr or (n) 
DHFR inserted between the DraIII and BfrBI sites as shown in Figure 1.
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sion screen and quantitation of total and soluble protein
expression was performed as for the N-terminal tag study.
Figure 3 shows the fluorescence western blots for this C-
terminal tag study. Here a greater number of constructs
were observed with either undetectable or low levels of
expression compared with the N-terminal tag study. Table
3 quantitates the Western blot data for the intact fusion
products, with expression yields greater than 2 mg/l in
bold. The last row of the table describes the average
expression yield for each C-terminal fusion partner. For
total protein expression levels there are large expression
level differences observed between the various C-terminal
tags. The C-terminal decahistidine tag was particularly
poor here with an average total expression yield of only
0.7 mg/l compared with 7.3 mg/l when this tag was fused
to the N-terminus. In contrast the C-terminal MBP-H10
tag resulted in an average total expression yield of 20.2
mg/l. The ranking of the C-terminal fusion partners in
promoting total expression was MBP-H10 > GST-H10 >
V5-H6 > Trx-H10 > Dhfr-H10 > DHFR-H10 > GFP-H10 >
H10.
MBP-H10 was the most effective tag at the C-terminus to
promote protein solubility with an average construct full-
length soluble yield of 5.0 mg/l, which compares well
with an average of 5.8 mg/l when this tag is fused at the N-
terminus. The order of C-terminal tags to promote soluble
expression was similar for total expression: MBP-H10 >
GST-H10 > V5-H6 > Dhfr-H10 ~ GFP-H10 ~ Trx-H10 >
H10 ~ DHFR-H10. Thioredoxin was not as effective a
solubility enhancing tag when fused at the C-terminus
with an average soluble yield of only 0.7 mg/l compared
with 6.0 mg/l when fused to the N-terminus.
Several correlations with protein features are seen when
one groups the MPB fusions according to soluble protein
expression levels. For the first group, where soluble
expression levels were in the range of 5 – 50 mg/l, the
average molecular weight, pI and GRAVY score were 20.6
Table 3: C-Terminal fusion expression comparison
C-TERMINAL FUSION
Protein (domain) V5-H6 H10 GFP-H10 GST-H10 Trx-H10 MBP-H10 Dhfr-H10 DHFR-H10
T ST STS T S TS T S TSTS
CASP2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
CCND2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
CD44 1.37 0.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
CDK2 23.47 12.30 1.88 1.30 0.70 0.19 0.53 0.08 0.86 0.16 7.52 3.48 5.82 0.51 0.00 0.00
CDK4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.13 0.00 0.00 0.00 2.07 0.44 0.00 0.00
CDKN1B 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.59 0.61 0.00 0.00 5.76 0.00
CDKN2A 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.59 0.56 0.00 0.00 0.48 0.22 0.00 0.00
Efna1 10.64 8.29 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.03 2.30 1.23 0.00 0.00 5.24 0.56
Efna1 (EC) 1.71 0.46 2.76 0.58 0.25 0.00 19.99 0.24 3.71 0.00 31.94 15.60 14.01 0.00 1.10 1.02
Efnb2 (EC1) 7.91 0.37 0.43 0.04 0.32 0.04 0.56 0.00 2.53 0.00 6.30 0.80 0.00 0.24 5.84 0.00
Efnb2 (EC2) 3.57 0.38 0.52 0.11 0.54 0.06 0.00 0.00 2.08 0.00 3.53 1.72 2.59 0.00 0.00 0.00
EGFR (TK) 1.14 0.00 0.00 0.00 0.00 0.00 0.28 0.00 12.76 1.11 3.03 0.25 2.07 0.00 0.00 0.00
Epha2 (LB) 3.97 0.27 0.00 0.00 0.15 0.00 2.37 0.00 4.33 0.42 19.33 8.60 7.42 0.00 0.00 0.00
Ephb2 (LB) 15.17 7.46 0.00 0.00 0.00 0.00 0.64 0.00 2.34 0.94 11.93 7.93 2.48 0.37 12.65 0.00
Ephb2 (SAM) 0.27 0.03 0.00 0.00 0.29 0.08 43.05 0.00 0.98 0.10 156.52 20.33 33.57 7.37 2.20 0.00
Ephb2 (TK) 43.00 1.89 8.85 0.12 0.00 0.00 205.64 2.13 24.04 0.00 49.99 3.01 27.02 1.06 0.00 0.00
Fli1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.11 0.00 1.10 0.00 0.00 0.00 7.14 0.00
FOS 4.72 0.27 0.22 0.00 0.92 0.49 0.00 0.00 0.11 0.00 1.16 0.62 0.00 0.00 4.35 0.00
GATA2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
GFP 8.14 1.38 1.11 0.67 12.94 9.86 2.03 2.01 21.50 4.78 118.38 40.52 4.66 2.93 9.56 2.74
GRB2 15.66 5.41 0.71 0.17 3.55 3.02 2.43 1.70 5.78 3.48 110.84 14.48 4.83 3.04 1.30 0.00
HRAS 19.21 6.44 0.29 0.25 11.49 6.46 0.56 0.39 1.06 0.37 12.32 10.07 3.21 3.01 0.75 0.57
JUN 6.75 0.00 0.31 0.00 0.00 0.00 0.48 0.00 1.41 0.00 8.81 0.35 0.00 0.00 7.79 0.00
MAD 9.76 2.62 3.94 5.05 0.49 0.13 1.37 0.00 5.91 3.34 19.02 6.94 1.86 0.13 0.88 0.00
MAX 0.00 0.00 0.00 0.00 0.71 0.53 101.26 80.86 1.59 0.62 9.70 5.17 5.82 3.48 0.94 0.00
Mdm2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mdm2 (p53-bd) 1.10 0.25 0.60 0.14 3.94 0.33 2.50 0.47 69.23 3.03 19.57 3.82 5.46 0.83 0.00 0.00
MMP1 12.51 0.85 0.00 0.00 0.00 0.00 3.27 0.00 0.00 0.00 0.00 0.00 4.29 0.00 0.52 0.00
RAF1 (Ras-bd) 0.48 0.06 0.00 0.00 0.45 0.16 0.96 0.19 2.66 0.71 5.83 1.63 2.08 1.07 0.00 0.00
Trp53 0.52 0.07 0.00 0.00 0.00 0.00 0.23 0.00 3.59 0.91 5.66 2.44 1.40 0.79 2.76 0.00
AVERAGE 6.37 1.65 0.72 0.28 1.23 0.71 12.94 2.94 5.75 0.69 20.21 4.99 4.37 0.85 2.29 0.16
Numbers correspond to total (T) or soluble (S) expression yield (mg/l). Yields greater than 2 mg/l are in bold.BMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
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KDa, 5.9 and -0.58 respectively. The average numbers of
contiguous hydrophobic amino acids, low complexity
and coiled-coil regions were 3.1, 0.56 and 0.22 respec-
tively. The second group displayed soluble expression lev-
els between 1 – 5 mg/l. Here, the average molecular
weight, pI and GRAVY score were 25.1 KDa, 7.9 and -0.39
respectively and the average numbers of contiguous
hydrophobic amino acids, low complexity and coiled-coil
regions were 4.3, 0.71 and 0 respectively. The last group
displayed soluble expression levels between 0 – 1 mg / l.
Here the average molecular weight, pI and GRAVY score
were 41.1 KDa, 6.2 and -0.51 respectively and the average
numbers of contiguous hydrophobic amino acids, low
complexity and coiled-coil regions were 5, 2.43 and 0.21
respectively. There were representatives of nuclear, cyto-
plasmic and extra-cellular proteins in all three groupings.
Expression of a test set of 95 mammalian proteins
A diverse set of proteins were chosen to test the conclu-
sions of this study (Table 4). They range from proteins
that are well annotated, some of which have been
expressed in E. coli previously (Nfkb1), to those that con-
tain no PfamA domains and have not been expressed in E.
coli  previously (Maat1, BC031407, Ttyhl,
1500001H12RIKEXT2, Ext2, KIAA1136, G2 and
KIAA1549). They included 24 proteins not annotated as
PfamA domains, with unknown function. All cDNAs were
amplified from a primary cDNA library, cloned into
pDONR221 and sequence confirmed prior to transfer to
pDEST-N112-MBP (Figure 1) for expression as N-terminal
H10-MBP fusions. In some cases primers were designed to
clone protein fragments to express particular PfamA
domains or minimise the molecular weight or numbers of
low complexity (LC) regions or contiguous hydrophobic
amino acids (hp_aa). For proteins with no PfamA annota-
tions, such as BC031407, SMART sequence analysis [44]
was performed to identify the low complexity regions of
the protein and truncations performed accordingly. Pro-
tein expression and quantitation of intact soluble fusion
protein product was performed as for the N- and C-termi-
nal tag comparison study. The total and soluble expres-
sion levels (mg of protein per litre culture) are listed in the
last column of Table 4 together with selected protein fea-
tures. 63 of the 95 proteins yielded soluble expression lev-
els of greater than 1 mg/l and the average molecular
weight, number of LC regions and hp_aa for these pro-
teins was 24.4 kDa, 0.9 and 3.7 respectively. For the 32
proteins that failed to give soluble product of the correct
size, the average molecular weight, number of LC regions
and hp_aa was 37.1 kDa, 1.8 and 4.5 respectively.
Discussion
Correlation between protein properties and solubility
To guide future expression strategies for new proteins, par-
ticularly regarding the choice of expressing a full-length
protein in a bacterial or eukaryotic system and also where
to truncate multi-domain containing proteins, it is inter-
esting to investigate if the proteins expressed in a soluble
form in this study share any common properties. Recently
Goh et al. [45] used data generated by a structural genom-
ics consortium to examine the ability of proteins to
progress from cloning to expression and purification to
crystallisation. The data used was very large, consisting of
27,000 targets from over 120 organisms and a number of
important features were inferred that correlated with suc-
cess including percentage composition of charged resi-
dues, occurrence of hydrophobic patches and length.
Although a large study, there was a problem with interpre-
tation of all the data-sets as it was unclear whether targets
were simply waiting in the pipeline or had failed. Also
structural genomics targets are often initially biased in
favour of easy to express proteins, not representative of
the whole proteomes of these organisms.
The present study, focused on mammalian proteins from
several diverse families, examined the relationship
between successful soluble expression with various pro-
tein properties. Several protein features were identified in
this study to correlate with soluble expression, which had
not previously been shown experimentally. For both the
N and C-terminal tag expression studies it was observed
that the presence of several features did not correlate with
successful expression including protein pI, grand average
of hydropathicity index (GRAVY) [43], sub-cellular loca-
tion, the cysteine content as a percentage of the total
number of amino acids and the number of coiled-coils.
Protein pI has been linked to sub-cellular location [46]
with a bimodal distribution observed in bacterial and
archaeal genomes and trimodal pattern in eukaryotes.
Proteins are thought to be less soluble at a pH environ-
ment near their pI. GRAVY simply calculates overall
hydrophobicity of the linear polypeptide sequence with
increasing positive score indicating greater hydrophobic-
ity, but no account is taken of the way the protein folds in
three dimensions or the percentage of residues buried in
the hydrophobic core of the protein. In a recent study
Luan et al. [47] tested the soluble expression of 10,167
full-length C. elegans ORFs and found that protein hydro-
phobicity was an important factor for an ORF to yield a
soluble expression product. This different result may be
attributable to the fact that the C. elegans study included a
greater proportion of membrane proteins. Therefore the
lack of correlation between GRAVY score and soluble
expression we observed may be true for non-membrane
proteins or for proteins where the trans-membrane
domain has been deleted.
There was a strong correlation between successful soluble
expression and molecular weight of the protein. Small
proteins with an average molecular weight of 22.8 KDaBMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
Page 10 of 17
(page number not for citation purposes)
Table 4: Expression levels of mammalian proteins expressed with N-terminal H10-MBP fusions, with selected protein features
No. Protein Accession 
No.
PfamA Domaina Construct MW 
(kDa)
hp_aa LC Total 
Expression 
(mg / l)
Soluble 
Expression 
(mg / l)
31 TAL1 P17542 HLH 179–331/331 16.5 3.0 1.0 13.2 8.3
32 ELF1 P32519 Ets 2–619/619 67.4 6.0 5.0 0.0 0.0
33 ELF1 P32519 nab 2–167/619 18.0 4.0 2.0 14.6 14.6
34 ELF1 P32519 Ets 204–619/619 45.4 6.0 2.0 0.0 0.0
35 ELF1 P32519 na 316–619/619 32.2 3.0 1.0 0.0 0.0
36 ELF1 P32519 Ets 204–306/619 12.1 6.0 0.0 65.0 19.3
37 Elf1 Q60775 Ets 2–612/612 66.1 6.0 4.0 24.0 23.5
38 Elf1 Q60775 Ets 2–306/612 34.0 6.0 3.0 60.6 27.2
39 Elf1 Q60775 na 2–167/612 17.8 4.0 2.0 8.6 8.4
40 Elf1 Q60775 Ets 204–612/612 44.2 6.0 1.0 15.5 10.4
41 Elf1 Q60775 Ets 204–306/612 12.1 6.0 0.0 18.5 12.1
42 Elf1 Q60775 na 316–612/612 30.7 3.0 0.0 0.0 0.0
43 Gata1 P17679 GATA × 2 2–413/413 42.5 3.0 6.0 16.0 14.3
44 Gata1 P17679 GATA × 2 2–319/413 33.8 3.0 5.0 67.0 15.8
45 Gata1 P17679 na 2–182/413 18.6 3.0 3.0 9.7 7.2
46 Gata1 P17679 GATA × 2 191–413/413 23.1 3.0 5.0 19.7 9.6
47 Gata1 P17679 GATA × 2 191–319/413 14.3 3.0 0.0 0.0 0.0
48 Gata2 O09100 GATA × 2 2–480/480 50.3 5.0 5.0 0.0 0.0
49 Gata2 O09100 na 2–189/480 19.4 4.0 2.0 0.0 0.0
50 Gata2 O09100 GATA × 2 275–480/480 22.4 5.0 2.0 0.0 0.0
51 Gata2 O09100 GATA × 2 275–402/480 14.2 1.0 1.0 0.0 0.0
52 Fli1 P26323 SAM_PNT, Ets 2–452/452 50.9 3.0 1.0 0.0 0.0
53 Fli1 P26323 SAM_PNT, Ets 2–363/452 41.7 3.0 0.0 134.5 61.0
54 Fli1 P26323 SAM_PNT 2–198/452 22.2 3.0 0.0 121.2 86.8
55 Fli1 P26323 SAM_PNT, Ets 114–452/452 38.6 3.0 1.0 61.0 38.2
56 Fli1 P26323 SAM+ETS 114–363/452 29.4 3.0 0.0 96.5 73.1
57 Fli1 P26323 SAM_PNT 114–196/452 10.0 3.0 0.0 71.8 51.7
58 Fli1 P26323 Ets 280–452/452 20.1 3.0 1.0 28.6 16.3
59 Fli1 P26323 Ets 280–363/452 10.9 3.0 0.0 23.4 23.0
60 Lmo2 P25801 LIM × 2 2–158/158 18.2 3.0 0.0 106.7 23.8
61 Ldb1 P70662 LIM_bind 2–375/375 42.6 3.0 2.0 0.0 0.0
62 Ldb1 P70662 LIM_bind 2–273/375 31.9 3.0 0.0 133.8 62.0
63 Ldb1 P70662 LIM_bind 275–375/375 10.5 2.0 1.0 2.0 1.7
64 Lyl1 P27792 HLH 40–278/278 26.2 3.0 0.0 3.8 2.6
65 Lyl1 P27792 HLH 40–215/278 19.6 3.0 0.0 4.2 2.5
66 Lyl1 P27792 na 40–135/278 10.3 3.0 0.0 3.6 1.7
67 Lyl1 P27792 HLH 150–278/278 14.8 3.0 0.0 40.1 32.2
68 Lyl1 P27792 HLH 150–215/278 8.2 3.0 0.0 60.3 20.8
69 Ttr P07309 transthyretin 20–147/147 13.6 5.0 0.0 59.2 49.7
70 Pin1 Q9QUR7 WW, Rotamase 2–163/163 18.2 2.0 0.0 36.9 19.4
71 Whsc1 Q7TSF5 PHD × 2, PWWP, SET 2–558/558 63.8 4.0 2.0 9.4 1.3
72 Whsc1 Q7TSF5 PHD, PWWP, SET 2–373/558 43.0 4.0 0.0 21.6 12.4
73 Whsc1 Q7TSF5 PHD, PWWP 2–149/558 17.2 4.0 0.0 0.0 0.0
74 Whsc1 Q7TSF5 PWWP, SET, PHD 70–558/558 56.1 4.0 2.0 5.1 2.1
75 Whsc1 Q7TSF5 PWWP, SET 70–373/558 35.3 4.0 0.0 18.2 17.9
76 Whsc1 Q7TSF5 PWWP 70–149/558 9.5 4.0 0.0 56.8 14.6
77 Whsc1 Q7TSF5 SET 249–373/558 14.3 4.0 0.0 34.7 22.6
78 Maat1 NM_024227 na 2–257/257 30.0 3.0 0.0 2.7 2.4
79 BC031407 NM_145596 na 2–630/630 67.3 6.0 6.0 0.0 0.0
80 BC031407 NM_145596 na 2–455/630 48.5 6.0 5.0 0.0 0.0
81 BC031407 NM_145596 na 2–179/630 19.4 4.0 1.0 9.6 8.7
82 BC031407 NM_145596 na 178–630/630 48.0 6.0 5.0 0.0 0.0
83 BC031407 NM_145596 na 178–455/630 29.1 6.0 4.0 0.0 0.0
84 BC031407 NM_145596 na 413–630/630 23.7 4.0 1.0 0.0 0.0
85 Bzrp2 P50637 TspO_MBR 2–169/169 18.7 4.0 0.0 0.0 0.0
86 MGC19339 NM_145954 Aldedh 40–486/803 47.0 5.0 2.0 37.2 18.7
87 Bsg NM_009768 Ig × 2, V-set 28–323/389 32.4 4.0 0.0 61.2 36.6
88 Snx15 NM_026912 PX, MIT 2–337/337 37.6 4.0 1.0 32.4 32.0BMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
Page 11 of 17
(page number not for citation purposes)
did not require to be fused with solubility enhancing
proteins for soluble expression whereas proteins that
required to be fused with N-terminal MBP or Trx for solu-
ble expression had an average molecular weight of 40.4
KDa and those where the addition of a N-terminal fusion
could not rescue soluble expression had an average size of
51.4 KDa. The same pattern also emerged in the C-termi-
nal fusion study. The decreasing probability of successful
soluble expression of mammalian proteins with increas-
ing molecular weight is likely due to increasing protein
complexity, perhaps requiring specialised eukaryotic
chaperones for folding or stabilising binding partners. The
majority of proteins solubly expressed in this study con-
tained single domains and as fusion proteins were either
capable of self-folding or were folded with the aid of
prokaryotic chaperones. Braun et al. found a similar rela-
tionship with their set of 32 human proteins with 4 differ-
ent N-terminal fusions [30].
A correlation in this study was observed between increas-
ing numbers of contiguous hydrophobic amino (hp_aa)
acids (AILFWV) and soluble expression. This ranged from
an average of 3.8 hp_aa for those proteins not requiring a
N-terminal fusion for high level soluble expression to 5
hp_aa for proteins requiring a N-terminal fusion for
successful expression and 5.6 hp_aa where expression
failed under the conditions described here. This pattern
was also repeated in the C-terminal fusion study where
good expression proteins had an average of 3.1 hp_aa
whereas poor expression proteins had an average of 5
hp_aa. In a study of the sequences of 2753 non-mem-
brane proteins it was found that the sequences of three or
more consecutive hydrophobic residues are suppressed in
89 Snx15 NM_026912 PX 2–226/337 25.6 4.0 1.0 20.0 18.8
90 Atp2b2 Q9R0K7 Cation_ATPase_N 2–94/1198 10.4 2.0 0.0 42.1 24.7
91 Atp2b2 Q9R0K7 Cation_ATPase_N 1039–1198/1198 17.9 2.0 3.0 6.1 5.0
92 cdh23 Q99PF4 Cadherin 33–132/3354 11.1 4.0 0.0 174.7 38.8
93 Myo15 Q9QZZ4 SH3_2 2847–2937/3511 9.8 4.0 0.0 8.6 0.0
94 Myo7a P97479 SH3_1 1602–1672/2215 7.8 4.0 0.0 76.0 35.4
95 tmc1 Q8R4P5 na 2–193/757 22.9 3.0 3.0 0.0 0.0
96 Trvp4 NM_022017 na 500–718/871 24.6 9.0 0.0 0.0 0.0
97 Whrn XM_196324 PDZ 811–908/908 11.0 3.0 0.0 34.1 31.1
98 Espn NM_019585 WH2 2–253/253 28.0 3.0 2.0 5.5 3.8
99 Map2 P20357 Tubulin-binding 1657–1755/1828 10.6 2.0 0.0 47.1 46.8
100 Prom O54990 Prominin 124–162/867 4.3 2.0 1.0 16.3 8.5
101 GluR1 P23818 ANF_receptor 19–538/907 59.0 4.0 0.0 0.0 0.0
102 GluR2 P23819 ANF_receptor 22–545/883 58.6 4.0 0.0 0.0 0.0
103 Grin1 P35438 na 834–938/938 12.0 5.0 0.0 13.8 13.8
104 Grin2a P35436 na 23–555/1464 59.9 6.0 0.0 58.5 8.2
105 Grin2b Q01097 Lig_chan 656–817/1482 18.1 4.0 0.0 0.0 0.0
106 Dlgh2 NM_011807 PDZ 419–530/852 11.7 4.0 0.0 13.8 13.7
107 Dlgh4 Q62108 PDZ 311–394/724 8.7 4.0 0.0 37.4 29.2
108 Dlgh3 P70175 PDZ 402–509/849 11.7 5.0 0.0 0.0 0.0
109 Dlgh1 U93309 PDZ 432–572/927 15.1 5.0 0.0 26.7 23.4
110 Syngap1 XM_139847 RasGAP 405–615/1318 23.9 3.0 0.0 0.0 0.0
111 Grip1 Q925T5 PDZ 1–112/1034 9.6 3.0 0.0 0.0 0.0
112 Homer1 Q9Z2Y3 WH1 2–107/354 12.1 3.0 0.0 17.9 17.6
113 Homer3 Q99JP6 WH1 2–110/356 39.3 4.0 0.0 0.0 0.0
114 TtyhI Q9EQN7 na 263–450/450 20.6 5.0 0.0 35.6 28.3
115 1500001H12RIKEXT2 NM_021316 na 2–149/149 14.8 5.0 3.0 66.1 66.1
116 Ext2 NM_010163 na 99–392/718 33.0 4.0 0.0 18.5 3.5
117 KIAA1136 Q9ULT3 na 45–214/597 19.2 2.0 0.0 26.8 10.4
118 G2 Q12914 na 1046–1692/1692 71.3 5.0 3.0 0.0 0.0
119 KIAA1549 Q9HCM3 na 184–464/1865 29.5 5.0 4.0 3.5 0.0
120 Nfkb1 P25799 RHD 39–365/971 36.7 5.0 0.0 27.1 22.7
121 Nfkb1 P25799 RHD, TIG, Ank × 6, Death 2–971/971 105.5 7.0 3.0 0.0 0.0
122 RelA-p65 Q04207 RHD, TIG 18–306/549 32.9 4.0 0.0 24.1 18.2
123 RelA-p65 Q04207 RHD, TIG 2–549/549 60.0 5.0 2.0 0.0 0.0
124 RelB Q04863 RHD, TIG 102–418/558 35.8 4.0 0.0 46.0 25.9
125 myog P12979 HLH, Basic 2–224/224 25.1 3.0 1.0 25.8 12.4
Features listed as Table 1 except: aPfamA domains contained within expressed protein and bna – no PfamA domains annotated.
Table 4: Expression levels of mammalian proteins expressed with N-terminal H10-MBP fusions, with selected protein features BMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
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globular proteins [48]. Low complexity regions of pro-
teins are regions of a protein of biased composition con-
taining a small number of amino acids [33] and can have
a disordered structure important for protein function
[49]. Here we found that the greater the number of low
complexity regions contained within the target protein,
the less likely soluble expression would be achieved. This
was true for both the N- and C-terminal fusion protein
studies with 0.6 – 1 low complexity regions for proteins
easy to express in a soluble form to 2.4 – 3 low complexity
regions for proteins difficult to express. Low complexity
regions are less common in bacterial proteins and these
may be targets for proteolytic degradation in vivo.
Some interesting conclusions were drawn when soluble
expression was measured for an additional set of 95 mam-
malian proteins expressed as H10-MBP fusions (Table 4).
In several cases (ELF1, Fli1, Ldb1, BC031407, Nfkb1 and
RelA-p65) truncating the proteins to minimise the molec-
ular weight and the numbers of low complexity regions
and contiguous hydrophobic amino acids made the dif-
ference between failed expression and good soluble pro-
tein expression. For proteins such as BC031407, with no
annotated PfamA domains, it was found that truncating at
low complexity regions was a good method to identify a
fragment that could express in a soluble form of the cor-
rect size (protein 81). Although we found that successful
soluble expression of the 95 protein set correlated with
lower molecular weight, number of low complexity
regions and contiguous hydrophobic amino acids com-
pared with proteins that failed to express solubly with the
correct size, validating our earlier conclusions, there were
some exceptions. For example Elf1 and Gata1 both
expressed well despite having 4 and 6 low complexity
regions respectively and molecular weights of 66 and 42.5
kDa, whereas some smaller proteins such as the PDZ
domains of Dlgh3 and Grip1 failed to express. It may be
that there are additional protein features, such as the abil-
ity to form a stabilising interaction with a binding partner,
that are also important for soluble expression. Also ensur-
ing correct protein domain boundaries may be important
since the annotated Pfam domain boundaries, based on
sequence alignment, do not always match the structural or
folding domain boundaries.
Protein fusions that enhance protein solubility
There have been three comparative studies recently where
sets of proteins were cloned into several expression vec-
tors and the effects of the fusion partner on total and sol-
uble expression yield were examined. Hammarstrom et al.
[29] cloned 27 human proteins (MW < 20 Kda) into vari-
ous expression vectors and ranked the tags ability to pro-
mote soluble expression as Trx ~ MBP ~ Gb1 > ZZ > NusA
> GST > His6. Another study ranked tags in terms of
increased expression and yield after purification as GST ~
MBP > CBP > His6 when comparing the expression of 32
human proteins where the molecular weight varied from
17 – 110 kDa.[30] Here GST was preferred because of the
weak affinity between MBP and amylose resin. In a third
study of 40 different proteins (10 mammalian, 3 plant
and 2 insect) with 8 different tags MBP gave the best over-
all results in terms of total and soluble expression [31].
However, these studies used different combinations of
promoter and fusion partner, so it was unclear whether
the observed effect was purely due to expression with the
fusion partner or variable rates of transcript synthesis that
would also affect translation rates.
In this study it was found that, on average, N-terminal
fusion partners are preferable for optimal protein expres-
sion. When proteins are expressed with their native N-ter-
minus, as in our C-terminal fusion proteins, total
expression levels can be more variable than when
expressed with a constant N-terminal tag. This may be
because of variable RNA secondary structures in the
region around the start codon which could interfere with
ribosome binding. An additional explanation is that dur-
ing translation the expressed protein emerges from the
ribosome first and initiates an incorrect, irreversible, fold-
ing pathway before the soluble fusion partner has been
translated and folded. The mis-folded protein would be
ubiquitin labelled and targeted to the proteasome for deg-
radation resulting in lower total expression levels. This
scenario is more likely when expressing mammalian pro-
teins in a bacterial system which lacks specific eukaryotic
chaperone proteins. It has been shown previously that
proteins prone to mis-folding and aggregation can arrest
GFP folding when fused at the C-terminus [17]. However,
when the soluble protein is fused at the N-terminus, this
would be translated first and perhaps increase the solubil-
ity of the downstream protein domain folding intermedi-
ates, increasing their half lives prior to irreversible
aggregation. This would allow greater reversibility in the
individual steps along the folding pathway and increase
the probability that the protein would eventually reach
the lowest free energy native conformation.
It was found that Trx and MBP were the best N-terminal
protein fusions to promote protein solubility. The best C-
terminal fusion to promote protein solubility was MBP
and this may be acting as a true intra-molecular chaperone
[50], able to promote folding of the N-terminal protein
fusion. The mechanism could be due to direct binding to
folding intermediates [51], allowing stabilisation prior to
correct folding and inhibition of aggregate formation. The
observation that MBP was effective at enhancing soluble
expression when fused at the C-terminus, in contrast to
thioredoxin, suggests that MBP can actually reverse the
process of incorrect folding that would have started prior
to the translation of the downstream MBP. This propertyBMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
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was not observed for thioredoxin when fused to the C-ter-
minus suggesting either that, in three-dimensions, differ-
ent proximal faces of the fusion partners have different
solubility enhancing properties or that thioredoxin does
not posses any chaperone properties and acts only as a
solubility enhancer. Alternatively, the folding of thiore-
doxin may be more prone to inhibition than MBP. Also
there are examples where MBP fusions can form soluble
inclusion bodies [52,53], and this cannot be ruled out as
a possibility here, although there are also several examples
where MBP fusion proteins are fully functionally active
[50,52,54,55].
It must be stressed here that although protein solubility is
a useful indicator of correct folding, additional measure-
ments need to be performed to give supporting evidence
for correct folding. These may include removing the pro-
tein fusion with a protease and analysis of the cleaved pro-
tein of interest by a variety of biophysical and functional
assays such as analysis of monodispersity by light scatter-
ing [52], NMR [56,57], CD spectropolarimetry, bis-ANS
binding [53], ligand binding or enzymatic activity. In this
study a protease cleavage site was not included in the vec-
tor constructs because the main use of the proteins gener-
ated in our laboratory will be in high-throughput
antibody production where the cleavage of the fusion
partner is unnecessary.
GFP did not significantly enhance soluble protein expres-
sion when fused to the C-terminus of the proteins in this
study, supporting the use of this tag as an indicator of sol-
uble protein expression of fused ORFs.[17,41] The obser-
vation that the V5-His6 tag resulted in a higher average
soluble expression level than the His10 tag (1.7 compared
with 0.3 mg/l) indicates that the identity of the peptide tag
can also affect overall solubility of expressed proteins.
Conclusions
What guidelines have emerged from this study in develop-
ing a strategy for the production of soluble mammalian
proteins in E. coli? If the protein has a molecular weight of
less than 30 KDa and contains 1 or less low complexity
regions and less than 4 contiguous hydrophobic amino
acids expression of the full-length protein in E. coli should
give good levels of soluble protein. As a generic strategy
we would recommend expressing the protein with a
fusion partner and found MBP and Trx to be the best
fusions to enhance protein solubility as N-terminal tags
with MBP being superior as a C-terminal fusion. C-termi-
nal fusions are desirable for proteins such as the P450s
where N-terminal tags can inhibit functional activity.
When fused to an optimal fusion partner, nuclear, cyto-
plasmic and extra-cellular domains were equally likely to
be expressed solubly. For larger proteins over 50 KDa,
truncations should be considered to express specific pro-
tein domains and to minimise the molecular weight,
number of low complexity regions and contiguous hydro-
phobic amino acids. In conclusion, this study will help
enable a systematic expansion in the number mammalian
proteins and domains that can be successfully expressed
in E. coli as soluble product, and also predict which are
best targeted for a eukaryotic expression system.
Methods
Materials
Oligonucleotides were synthesised by Qiagen-Operon
(Cologne, Germany) or Sigma-Genosys (Haverhill, UK).
All restriction enzymes were from New England Biolabs
(Hitchin, UK). The vectors pET-DEST42, pDEST17 and
pDONR201 and E. coli DB3.1 and BL21(DE3)Star pLysS,
Gateway BP and LR clonase enzyme mix, pre-cast 4–12 %
NuPAGE Bis-Tris gels and PVDF membranes (0.45 µm
pore size) were all from Invitrogen (Paisley, UK). Entry
plasmids in both open (minus stop codon) or closed for-
mat (plus stop codon) containing the full-length genes for
GRB2, HRAS, JUN, FOS, MAD, MAX, CDK2, CDK4,
CDKN1B, CASP2, MMP1, CDKN2A and CD44 were pro-
vided by Pascal Braun and Josh LaBaer (Harvard Institute
of Proteomics, Cambridge, USA). A full length clone con-
taining the full-length human EGFR ORF was provided by
the RIKEN BioResource Center (Tsukuba, Japan) and
Efna1 from the Mammalian Gene Collection (MGC)
archived at the Wellcome Trust Sanger Institute (Hinxton,
UK). First strand synthesis human and mouse cDNA was
from BD Biosciences (Oxford, UK). Plasmid, gel extrac-
tion and PCR purification kits and 6xHis protein ladder
were purchased from Qiagen (Crawley, UK). The expres-
sion strain BL21(DE3), BugBuster protein extraction rea-
gent and His tag monoclonal antibody was from Merck
Biosciences (Nottingham, UK). The 96-well multiscreen-
DV durapore filter plate with 0.65 µm pore size was from
Millipore (Watford, UK) and Cy5-labelled goat anti-
mouse IgG from Amersham Biosciences (Little Chalfont,
UK). Europium labelled antibodies and DELFIA reagents
were from Perkin Elmer (Beaconsfield, UK) and all other
chemicals unless otherwise stated were from Sigma-
Aldrich (Gillingham, UK).
N-Terminal fusion GATEWAY destination vector 
construction
To prepare pET-DEST42-MCS, a multi-cloning site was
inserted into pET-DEST42 (Invitrogen) at nt396, between
the shine-dalgarno sequence and the attR1 recombination
site, encoding the recognition sequences for NdeI, KpnI,
DraIII and BfrBI. Inverse or whole plasmid PCR was per-
formed on pET-DEST42 with 5'-phosphorylated PAGE
purified primer pairs 20 (5' TACCCACGAAGTGATGCAT-
ACAAGTTTGTACAAAAAAGCTGAACG 3') and 21 (5'
CCCATATGTATATCTCCTTCTTAAAGTTAAACAAAAT-
TATTTCTAGAG 3') in a 20 µl reaction containing 10 ngBMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
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pET-DEST42, 0.3 µM primers 20 and 21, 20 mM Tris-HCl
(pH 7.5), 0.5 mM DTT, 200 µM each of dATP, dCTP,
dGTP and dTTP, 1 mM MgSO4, and 0.5 unit KOD hot start
DNA polymerase (Novagen). PCR cycling conditions
were: 94°C – 2 mins followed by 15 cycles of 94°C – 15
s, 59°C – 30 s, 68°C – 9 mins. The 7468 bp PCR product
was purified using a PCR purification spin column (Qia-
gen) and eluted with 30 µl of 10 mM Tris-HCl (pH8.5),
digested with 20 units of DpnI enzyme at 37°C for 4 hrs,
to remove methylated plasmid DNA, purified by spin col-
umn and an intramolecular ligation reaction performed
using 16 ng of linear PCR product and 5 units T4 DNA
ligase and the buffers from the rapid ligation kit (Roche).
The ligated PCR product was used to transform E. coli
DB3.1 and the resultant pET-DEST42-MCS plasmid DNA
prepared and sequence confirmed. Insert 1, encoding a
decahistidine tag with a 5'-NdeI site and blunt 3' end, was
prepared by PCR with primer pairs 22 (5' GGAATTCCAT-
ATGAAUCAC 3') and 24 (5' pGTGATGGTGATGGTGAT-
GGTGATGGTGATTCATATGGAATTCC) and insert 2
encoding a decahistidine tag flanked by a 5'-NdeI site and
3'-KpnI site was prepared with primer pairs 22 and 26 (5'
CGGGGTACCATGGTGATGGTGATGGTGATGGTGAT-
GGTGATTCATATGGAATTCC 3'). PCR reactions were as
above except the annealing temperature dropped to 44°C,
extension time to 10 s and 12 cycles employed. Insert size
was checked by 10 % TBE-PAGE and purified by a nucle-
otide removal kit (Qiagen). Expression vectors (b) pDEST-
N110 and pDEST-N112 (Figure 1) were prepared by
digestion of inserts 1 and 2 with NdeI only or NdeI and
KpnI combined respectively, purified by spin column and
ligated in a 1:1 ratio to NdeI, BfrBI or NdeI, KpnI digested
pET-DEST42-MCS respectively prior to transformation of
E. coli DB3.1. Inserts encoding MBP, GFP, GST or Trx
flanked by a 5' DraIII site and a 3' blunt end were gener-
ated by PCR amplification from the plasmids pMALc2
(New England Biolabs), pET41a or pET32 (Novagen)
respectively The primer pairs for MBP were 78 (5'
TTATTACACGAAGTGAAAATCGAAGAAGGTAAACTGG-
TAATC 3') and 79 (5' pGTTCGAGCTCGAATTAGTCT-
GCGCGTCTTTC), for GFP 84 (5'
TTATTACACGAAGTGGCTAGCAAAGGAGAAGAACTTT-
TCACTGGAG 3') and 85 (5' pTTTGTAGAGCTCATCCAT-
GCCATGTGTAATC 3'), for GST 86 (5'
TTATTACACGAAGTGTCCCCTATACTAGGTTATT-
GGAAAATTAAGGG 3') and 87 (5' pATCCGATTTTGGAG-
GATGGTCGCCACC 3') and for Trx 88 (5'
TTATTACACGAAGTGAGCGATAAAATTATTCACCT-
GACTGAC 3') and 89 (5' p CAGGTTAGCGTCGAG-
GAACTCTTTC 3'). The inserts were digested with DraIII
and ligated with DraIII, BfrBI cut pDEST-N112 vector to
create the GATEWAY destination vectors pDEST-112-
MBP, pDEST-112-GFP, pDEST-112-GST, pDEST-112-Trx.
C-Terminal fusion GATEWAY destination vector 
construction
pDEST-C101 was designed to insert a decahistidine
encoded sequence between the attR2 recombination site
and T7 transcription termination region. pDEST-C102 is
as C101 except a DraIII, BfrBI site was inserted down-
stream of the attR2 recombination site. Inverse PCR was
performed as described above with primer pairs 1 (5'
pCACCATCACCATCATCACCATCACCATTGAGTTT-
GATCCGGC) and 2 (5' pATGCACCACTTTGTACAA-
GAAAGCTGAAC) to generate pDEST-C101 and primer
pairs 1 and 3 (5' pATGCATACCACTCACTTCGTGCAC-
CACTTTGTACAAGAAAGCTGAAC) to prepare pDEST-
C102. Murine and human dihydrofolate reductase (Dhfr
and DHFR respectively) inserts flanked by a 5' DraIII site
and blunt end at the 3' were amplified from MGC clones
using the primer pairs 82 (5' TTATTACACGAAGTGCGAC-
CATTGAACTGCATCGTCGCCGTG) and 83 (5' pGTCTT-
TCTTCTCGTAGACTTCAAACTTATAC 3') for Dhfr and 80
(5' TTATTACACGAAGTGGGTTCGCTAAACT-
GCATCGTCGCTGTG) and 81 (5' pATCATTCTTCTCAT-
ATACTTCAAATTTG) for DHFR. The DraIII digested
inserts were ligated with DraIII, BfrBI digested pDEST-
C102 vector to create pDEST-C102-MBP, GFP, GST, Trx,
Dhfr and DHFR as shown in Figure 1.
cDNA isolation and expression clone generation
A nested PCR strategy was used to isolate protein encod-
ing ORFs directly from cDNA adapted for GATEWAY clon-
ing from the method described by J. E. Collins et al. [34].
Briefly 2 sets of primer pairs were designed, the first pair
of optimised primers binding 1 – 200 bp 5' and 3' of the
ORF using DS-Gene software (Accelerys) and a second set
of primers targeted to the beginning and end of the ORF.
All primers were designed with melting temperatures
around 60°C. PCR 1 contained 50 pg of either human
universal QUICK-clone II cDNA (Clontech) or 50 pg of a
mixture of mouse brain, heart, kidney, liver, smooth mus-
cle, spleen, testis and 7, 11, 15 and 17-day embryo
QUICK-clone cDNA (Clontech), 0.25 µM primers, 20 mM
Tris-HCl (pH 7.5), 0.5 mM DTT, 200 µM each of dATP,
dCTP, dGTP and dTTP, 1 mM MgSO4, and 0.5 unit KOD
hot start DNA polymerase (Novagen) in a total volume of
20 µl. The PCR reaction consisted of 94°C – 2 mins, and
30 cycles of 94°C – 15 s, 55°C – 30 s, 68°C – 2.5 mins
followed by 68°C – 5 mins. A 50-fold dilution of the PCR
1 reaction was made for the second 30 cycle PCR contain-
ing the ORF specific primers. Linkers were added to these
primers encoding half the attB1 and attB2 sites for for-
ward and reverse primers respectively. For entry clone gen-
eration to be transferred to N-terminal tag expression
vectors the 5'-linkers for the forward and reverse primers
were 5' AAAAAGCAGGCTCT 3' and 5' AGAAAGCTGGGT-
TCTA 3' respectively with the reverse primer adding a stop
codon. For inserts destined to the C-terminal tag expres-BMC Biotechnology 2004, 4:32 http://www.biomedcentral.com/1472-6750/4/32
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sion vectors the forward and reverse primers were 5'
AAAAAGCAGGCTTCGAAGGAGATAGAACCATGG 3' and
5' AGAAAGCTGGGTT 3' respectively with the forward
primer encoding the shine-dalgarno and kozak sequences
and start codon. PCR 2 products were analysed by 1 %
TBE-agarose electrophoresis[58] and correct size frag-
ments were then subjected to an adapter PCR step to com-
plete the flanking attB1 and attB2 sites. This consisted of
a PCR reaction as described above using 1 µl of a 50-fold
dilution of the PCR 2 reaction in a total volume of 20 µl
and primer pair 113 (5' GGGGACAAGTTTGTA-
CAAAAAAGCAGGCT 3') and 114 (5' GGGGACCACTTT-
GTACAAGAAAGCTGGGT 3') except that the annealing
temperature was 45°C, only 12 cycles were used and
extension time was 2 mins. The products of the adapter
PCR were purified by a 96-well PCR clean-up kit (Qia-
gen), eluted in 100 µl 10 mM Tris-HCl (pH8.5) and had
an average concentration of 40 ng /µl. Recombinational
cloning of attB flanked PCR products with an attP con-
taining pDONR vector to generate a set of entry plasmids
was as described previously [35] except that pDONR221
(Invitrogen) was used. The ORFs within sequence con-
firmed attL containing entry plasmids were then recom-
bined the various attR destination vectors described above
to generate sets of expression plasmids. The LR recombi-
nation reactions [35] were used to transform E. coli DH5α
cells, miniprep plasmid DNA prepared and this used to
transform the various BL21(DE3) expression strains used
in this study.
Expression screening and quantitation
All BL21(DE3) transformants were selected and propa-
gated in the presence of 100 µg/ml ampicillin. A single
antibiotic resistant colony was used to inoculate 0.5 ml
2xYT media in a 96-deep well block containing the appro-
priate antibiotics and shaken at 210 rpm at 37°C. When
the average OD600 had reached 1 (3 hrs for BL21(DE3)),
60 µl was transferred to 1.2 ml 2xYT media in a 96-deep-
well block containing the appropriate antibiotics, placed
on a shaking incubator at 37°C and when the OD600
reached 0.5 (2 hrs for BL21(DE3)) IPTG added to a final
concentration of 1 mM and shaking continued at 25°C
for 12 hours. Total protein was analysed by transferring a
20 µl aliquot of the induced culture to a 96-well PCR plate
containing 20 µl of 2 × NuPage LDS loading buffer (Invit-
rogen), 0.1 M DTT, heated to 95°C for 10 mins and
cooled on ice prior to loading 10 µl on a 17-well 4–12 %
NuPAGE Bis-Tris gels with a multi-channel gel loading
syringe (Hamilton). Soluble protein was extracted by
transferring 290 µl of induced culture to a shallow well
plate, centrifugation at 3000 g for 5 mins, supernatant
removed and cells were resuspended in 58 µl BugBuster
containing 1.4 units of benzonase and 58 units of recom-
binant lysozyme (Novagen). For the C-terminal tag and
expression strain comparison this buffer was also
supplemented with 0.58 µl protease inhibitor cocktail set
III 10-fold diluted in DMSO (Novagen). The cell-pellets
were resuspended with a multi-channel pipette and incu-
bated with slow shaking for 20 mins at room temperature
prior to transfer to 96-well multiscreen-DV durapore filter
plates with 0.65 µm pore size (Millipore). The filter plate
was placed on top of a shallow 96-well plate and centri-
fuged at 1000 g for 2 mins. 4 µl of the filtrate was then
added to a 96-well plate containing 5 µl of 4 × NuPage
LDS loading buffer (Invitrogen), 11 µl of 182 mM DTT,
the plate heated at 95°C for 5 mins and loaded onto a 17-
well 4–12 % NuPAGE Bis-Tris gel. A His-tagged molecular
weight ladder (Qiagen) was also loaded onto each gel. Gel
electrophoresis and electro-transfer to PVDF membrane
was as described.[58] Blots were blocked with 3 % Marvel
milk powder in PBS-Tween (PBS with 0.1% Tween) either
1 hour at room temperature or over-night at room-tem-
perature, washed with PBS-Tween and incubated with 40
ng/ml anti-His5 tag monoclonal antibody (Novagen), 3
% Marvel, PBS-Tween for 1 hr, washed 3 × PBS-Tween,
incubated with 1 µg/ml Cy5 labelled goat anti-mouse in
3% Marvel, PBS-Tween for 1 hr, washed 3 × PBS-Tween
and 2 × PBS and blots dried at 37°C for 10 mins between
blotting paper. The blots were scanned on a Typhoon
8600 variable mode imager (Amersham) with fluores-
cence scan mode, 633 nm excitation laser, 670 nm emis-
sion filter, 600 V PMT and 200 µm / pixel scan resolution.
The integrated fluorescence intensity volumes of bands on
the gel were quantitated using ImageQuant TL software
(Amersham). Conversions to protein yield were made by
using a calibration curve of purified His-tagged single
chain antibody (scFv). Differences between the molecular
weight (MW) of the scFv (31 KDa) and each expressed
fusion protein were taken into account by multiplying
each protein quantitation by the ratio MW construct
(KDa) / 31. The numbers were normalised to eliminate
blot to blot variation using a His-tagged molecular weight
ladder (Qiagen).
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